Rezolute, Inc..
RZLT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Rezolute, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic diseases that affect underserved patient populations. The company's primary focus is on developing treatments for rare metabolic disorders, including congenital hyperinsulinism (CHI) an...Show More
Better Health for All
20
Rezolute, Inc. is a clinical-stage biopharmaceutical company whose entire business is devoted to developing novel therapies for rare metabolic diseases, specifically congenital hyperinsulinism (cHI). This condition is a leading cause of recurrent hypoglycemia in newborns and infants, with potential for brain damage and other severe health problems.
1
Current treatment options for cHI are limited, with some medications being ineffective or causing side effects, and surgical removal of the pancreas sometimes being necessary.
2
The company's focus on addressing these unmet medical needs indicates an exceptional health benefit. The company is conducting clinical trials for its lead product candidate, RZ358, for the treatment of cHI, which implies adherence to ethical frameworks for clinical research.
Fair Money & Economic Opportunity
0
Rezolute, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, not a financial institution.
1
As such, it does not offer lending, deposit, or other consumer financial services. Therefore, all KPIs related to financial products, pricing, fees, lending compliance, customer wealth building, and financial literacy initiatives are not applicable to its core business model. The company's focus on rare diseases means it serves a specific, often underserved patient population in a medical context, but this does not translate to the financial inclusion metrics of the rubric, which are designed for financial services.
2
Fair Pay & Worker Respect
0
No specific, concrete quantitative data was found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While some articles contained qualitative employee reviews mentioning issues with pay, management, and work environment, and high turnover, these did not provide the specific numerical metrics required by the rubric for scoring.
1
Information on CEO compensation was available, but median employee compensation was not, preventing the calculation of the CEO-to-median pay ratio.
2
Fair Trade & Ethical Sourcing
0
The provided articles, consisting primarily of financial reports, legal filings, and clinical trial updates for Rezolute, Inc., do not contain any specific, concrete data points or information regarding the company's fair trade or ethical sourcing practices.
1
There is no evidence related to fair-trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity spend.
2
The documents explicitly state that information on these topics is not mentioned or available.
3
Honest & Fair Business
-40
Rezolute, Inc. adopted a Code of Business Conduct and Ethics on May 30, 2023, which includes details on reporting violations and anti-corruption/anti-bribery provisions.
1
However, specific details on the policy's strength, enforcement, or effectiveness are not provided.
2
The company has not mentioned any financial restatements and identified and remediated a material weakness in internal control over financial reporting related to pre-funded warrant accounting in the fiscal quarter ended March 31, 2024.
3
Consolidated financial statements are audited by Grant Thornton, LLP and Plante & Moran, PLLC.
4
The company uses external consultants for cybersecurity, and its financial statements are externally audited, indicating some independent verification of claims.
5
Kind to Animals
0
The provided articles confirm that Rezolute, Inc. has conducted animal testing, with RZ402 tested in animal models of DME and historical rat toxicology findings influencing FDA decisions regarding ersodetug clinical studies.
1
The company is also subject to federal, state, and local laws and regulations concerning the experimental use of animals.
2
However, the articles do not provide specific quantitative data or explicit policy details required to score any of the KPIs in the 'Kind to Animals' rubric. Information such as the percentage of products certified cruelty-free, the extent of non-animal testing methods employed, the number of animals used annually, investment in animal-free alternatives, or details on animal welfare policies are not present. Therefore, no KPIs can be scored based on the provided evidence.
No War, No Weapons
0
No information regarding Rezolute, Inc.'s involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding initiatives, or related policies was found in the provided articles.
1
Therefore, no assessment can be made against the 'No War, No Weapons' ethical value for any KPI.
Planet-Friendly Business
0
No evidence available to assess Rezolute, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No relevant evidence was found in the provided articles to assess Rezolute, Inc. (RZLT.US) against the 'Respect for Cultures & Communities' value. contains no relevant information. refers to a company named 'Resolute' that operates 'mine sites', which does not align with Rezolute, Inc.'s description as a clinical-stage biopharmaceutical company.
1
Therefore, the information in is not applicable to RZLT.US.
Safe & Smart Tech
0
No information relevant to Rezolute, Inc.'s performance on Safe & Smart Tech KPIs was found in the provided articles.
1
Zero Waste & Sustainable Products
0
No evidence available to assess Rezolute, Inc. on Zero Waste & Sustainable Products.